We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+2.93%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$182M
AUM Growth
-$9.72M
(-5.1%)
Cap. Flow
-$9.6M
Cap. Flow
% of AUM
-5.28%
Top 10 Holdings %
Top 10 Hldgs %
6.2%
Holding
508
New
65
Increased
160
Reduced
215
Closed
68
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dow Inc
DOW
|
+$1.19M |
| 2 |
Progressive
PGR
|
+$963K |
| 3 |
Hershey
HSY
|
+$960K |
| 4 |
DexCom
DXCM
|
+$934K |
| 5 |
Copart
CPRT
|
+$930K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lennar Class A
LEN
|
+$952K |
| 2 |
TJX Companies
TJX
|
+$909K |
| 3 |
Ameriprise Financial
AMP
|
+$902K |
| 4 |
Abbott
ABT
|
+$892K |
| 5 |
Home Depot
HD
|
+$885K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.65% |
| 2 | Financials | 14.09% |
| 3 | Technology | 11.21% |
| 4 | Energy | 10.21% |
| 5 | Materials | 8.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Oaktree Specialty Lending
OCSL
$1.05B
| $119K | 0.07% |
6,350
-6,663
| -51% | -$133K |
|
|
BLUE
327
DELISTED
bluebird bio
BLUE
| $117K | 0.06% |
1,840
+33
| +2% | +$3.77K |
|
|
BKCC
328
DELISTED
BlackRock Capital Investment Corporation
BKCC
| $116K | 0.06% |
33,485
-81,983
| -71% | -$299K |
|
329
Arbutus Biopharma
ABUS
$847M
| $113K | 0.06% |
37,197
-14,299
| -28% | -$40.3K |
|
|
SWTX
330
DELISTED
SpringWorks Therapeutics
SWTX
| $111K | 0.06% |
4,314
-1,664
| -28% | -$48.6K |
|
|
ISEE
331
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $110K | 0.06% |
4,539
-1,748
| -28% | -$38.3K |
|
|
PNT
332
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $108K | 0.06% |
14,902
-5,727
| -28% | -$42.5K |
|
333
Krystal Biotech
KRYS
$10.7B
| $105K | 0.06% |
1,306
-498
| -28% | -$39.1K |
|
334
Immunovant
IMVT
$7.93B
| $104K | 0.06% |
6,701
-2,575
| -28% | -$44.7K |
|
335
Kymera Therapeutics
KYMR
$8.66B
| $101K | 0.06% |
3,419
-1,310
| -28% | -$42.2K |
|
|
RAPT
336
DELISTED
RAPT Therapeutics
RAPT
| $101K | 0.06% |
688
-265
| -28% | -$53.6K |
|
337
Stoke Therapeutics
STOK
$1.84B
| $101K | 0.06% |
12,078
-4,637
| -28% | -$41.8K |
|
|
RXDX
338
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $100K | 0.06% |
936
-353
| -27% | -$40.6K |
|
|
VTYX
339
DELISTED
Ventyx Biosciences
VTYX
| $99.8K | 0.05% |
2,980
-1,145
| -28% | -$44.5K |
|
340
Crinetics Pharmaceuticals
CRNX
$8.88B
| $99.8K | 0.05% |
6,215
-2,383
| -28% | -$44.1K |
|
|
CMPS
341
Compass Pathways
CMPS
$1.47B
| $99.7K | 0.05% |
10,043
-3,853
| -28% | -$35.5K |
|
342
BioXcel Therapeutics
BTAI
$24.8M
| $98.9K | 0.05% |
331
-127
| -28% | -$54.2K |
|
343
Xencor
XNCR
$1.45B
| $98.9K | 0.05% |
3,545
-1,366
| -28% | -$42.1K |
|
|
CVAC
344
DELISTED
CureVac
CVAC
| $98.4K | 0.05% |
14,114
-5,421
| -28% | -$47.3K |
|
345
Intellia Therapeutics
NTLA
$1.51B
| $97.3K | 0.05% |
2,610
-1,000
| -28% | -$39.2K |
|
|
PNNT
346
Pennant Park Investment Corp
PNNT
$220M
| $95.8K | 0.05% |
18,143
-37,970
| -68% | -$215K |
|
347
Relay Therapeutics
RLAY
$4B
| $95.3K | 0.05% |
5,786
-2,218
| -28% | -$39.8K |
|
|
ACLX
348
DELISTED
Arcellx
ACLX
| $94.5K | 0.05% |
3,068
-1,177
| -28% | -$35.7K |
|
349
Kura Oncology
KURA
$793M
| $94K | 0.05% |
7,685
-2,950
| -28% | -$36.8K |
|
|
KDNY
350
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $93.8K | 0.05% |
4,052
-1,558
| -28% | -$37.1K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q1 2023 Portfolio in Review
As of Q1 2023, Virtus ETF Advisers held 508 positions worth $182M, down 5.1% from $191M the previous quarter. Its ten largest holdings account for 6.2% of the portfolio.
Virtus ETF Advisers withdrew a net $9.6M in Q1 2023, closing 68 positions and reducing 215 holdings. Its most notable exit was Lennar Class A, an estimated $952K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 26% of assets, down from 27% a quarter earlier, followed by Financials and Technology.
Against the trend, Virtus ETF Advisers opened a new position in Dow Inc worth $1.16M.
- Virtus ETF Advisers's largest Q1 2023 buy was Dow Inc: 21,099 shares worth $1.16M.
- Virtus ETF Advisers added most to Devon Energy in Q1 2023, an estimated $447K increase.
- Virtus ETF Advisers's biggest Q1 2023 reduction was LyondellBasell Industries, cutting an estimated $514K.
- Virtus ETF Advisers fully exited Lennar Class A in Q1 2023, selling an estimated $952K.
- Virtus ETF Advisers's ten largest holdings make up 6.2% of its $182M portfolio in Q1 2023.
- Virtus ETF Advisers opened 65 new positions and closed 68 in Q1 2023.
- Virtus ETF Advisers's portfolio value fell 5.1% quarter-over-quarter to $182M.
Based on Virtus ETF Advisers's 13F filing for Q1 2023, filed 15 May 2023.